Sam Kulkarni takes the helm at CRISPR Therapeutics as founding CEO steps down
After steering CRISPR Therapeutics to an IPO last year as the last of the big three gene editing companies to make the leap into the public markets, founding CEO Rodger Novak is stepping down and handing the reins over to the original chief business development officer, Samarth Kulkarni.
There’s no specific reason given for Novak’s departure, other than the generic “personal reasons” often cited during these kinds of changeups. Novak is staying on the board.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.